Fujifilm invests $2B on cell culture manufacturing

By The Science Advisory Board staff writers

January 7, 2021 -- Fujifilm plans to invest more than $2 billion to build a large-scale cell culture manufacturing site for biopharmaceuticals in the U.S.

The company's subsidiary, Fujifilm Diosynth Biotechnologies, will operate the new facility, which will provide drug substance manufacturing, fill-finish and assembly, packaging, and labeling services, according to the firm. The facility will house eight 20,000-L bioreactors with the potential to expand and add 24 more bioreactors of the same size.

The new compound will be located near an existing U.S. Fujifilm site, and is expected to begin operations in the spring of 2025, Fujifilm said.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here